While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run. The laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future.
All entries for: Cardiology
May 5, 2026
Biomarin Pharmaceuticals Inc
Neutral Outlook
San Rafael, CA
1000-5000 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
April 30, 2026
Ardelyx
Neutral Outlook
Waltham, MA
201-500 employees
While the impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Cardiology, Chronic Disease, Gastrointestinal, Metabolic Diseases, Multiple
Drug Type: Small Molecule
March 30, 2026
Cyclerion Therapeutics, Inc
Negative Outlook
Cambridge, MA
51-200 employees
The impact of healthcare reform and other governmental and private payor initiatives, as well as the Inflation Reduction Act of 2022, may harm our business.
Disease Area: Cardiology, Neurological Diseases
Drug Type: Small Molecule
March 11, 2026
Tenaya Therapeutics, Inc.
Neutral Outlook
South San Francisco, CA
51-200 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Cardiology, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
March 10, 2026
Esperion Therapeutics, Inc.
Neutral Outlook
Ann Arbor, MI
201-500 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Cardiology, Gastrointestinal, Metabolic Diseases
Drug Type: Small Molecule
March 9, 2026
Cumblerland Pharmaceuticals
Neutral Outlook
South San Francisco, CA
51-200 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our patent strategy in the long term.
Disease Area: Cardiology, Neurological Diseases, Rare Diseases, Respiratory Diseases
Drug Type: Small Molecule
March 9, 2026
Zevra Therapeutics
Neutral Outlook
Boston, MA
51-200 employees
On August 16, 2022, the Inflation Reduction Act (“IRA”), of 2022, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.
Disease Area: Cardiology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
March 9, 2026
Editas Medicine
Neutral Outlook
Cambridge, MA
201-500 employees
On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years
Disease Area: Cardiology, Hematology, Immune Diseases, Metabolic Diseases, Oncology, Rare Diseases
Drug Type: Biologic